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ABSTRACT 
Background: Hyperthermia plays a significant role in the chemo-radiotherapy 
effect in different malignancies. In this research, we treated Glioblastoma 
multiform (GBM) patients with hyperthermia (HT) along with the 
chemoradiation, in order to evaluate HT efficacy in terms of tumor volume 
changes, survival time, and probability. Materials and Methods:                  
Thirty-eight GBM patients were distributed into two groups identified as 
chemoradiation (CRT), and also CRT plus HT (CRHT). The Karnofsky 
Performance Status Scale (KPS) was done before, immediately and three 
months after treatments. Capacitive hyperthermia device was used at 
frequency of 13.56 MHz (Celsius 42+ GmbH, Germany) for HT one hour before 
the radiotherapy for 10-12 sessions. Patients in both groups underwent MR 
imaging (1.5 Tesla) before, 3 and 6 months after the treatments. Thermal 
enhancement factors (TEF) were attained in terms of clinical target volume 
changes, TEF(CTV), and survival probability (SP) or TEF(SP). Results: Age 
ranges were from 27-73 years (Mean=50) and 27-65 years (Mean=50) for CRT 
and CRHT groups, respectively. For 53% and 47% of cases biopsy and partial 
resection were accomplished in both groups, respectively. Means and 
standard deviations of tumor volumes were 135.42±92.5 and 58.4±104.1cm3 
before treatment in CRT and CRHT groups, respectively, with no significant  
difference (P= 0.2). TEF(CTV) value was attained to be as 1.54 and 1.70 for 
three and six months after treatments, respectively, TEF(SP) was also equal to 
the 1.90. Conclusion: HT enhanced the chemoradiation effects throughout 
the patient survival probability and KPS. TEF may reflect the hyperthermia 
efficacy for a given radiation dose. 
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